Trial Profile
A Pilot Study in Metastatic Advanced Thyroid Cancer Evaluating the Safety and Efficacy of Sorafenib.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2019
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Acronyms MATiSSe
- 24 Sep 2019 Status changed from recruiting to discontinued.
- 21 Jun 2011 New trial record